Lavine Sean D, Wang Mei, Etu Joshua J, Meyers Philip M, Joshi Shailendra
Department of Radiology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Neurosurgery. 2007 Apr;60(4):742-8; discussion 748-9. doi: 10.1227/01.NEU.0000255404.30904.CE.
Local intra-arterial infusions of verapamil and nicardipine have been used to treat human cerebral vasospasm. Only a few reports of early clinical experience with these medications are currently available, and limited data are available regarding their cerebral physiological activity. We assessed the efficacy of intracarotid administration of verapamil and nicardipine on augmenting cerebral blood flow of New Zealand White rabbits and compared the ability of these drugs with reverse topical endothelin (ET)-1-triggered vasospasm.
In the first group of New Zealand white rabbits, cerebral blood flow (laser Doppler) and systemic hemodynamic measurements were recorded at baseline and with increasing intracarotid doses of verapamil and nicardipine. In the second group, topical ET-1 (10(-4) mol/L) was applied in an acutely implanted cranial window. Dose responses to nonspecific reversal of ET-1-induced vasospasm were evaluated with intra-arterially administered nicardipine and verapamil.
The dose-response studies revealed that intracarotid administration of nicardipine, compared with verapamil, was more effective in augmenting cerebral blood flow. Topical ET-1-induced vasospasm was completely reversed by nicardipine and partially reversed by verapamil.
This study suggests that intra-arterially administered nicardipine is a more potent cerebral vasodilator and is superior to verapamil for treating ET-1-induced experimental cerebral vasospasm and supports further investigation of these agents in subarachnoid hemorrhage-induced vasospasm.
维拉帕米和尼卡地平的局部动脉内输注已被用于治疗人类脑血管痉挛。目前仅有少数关于这些药物早期临床经验的报告,且关于其脑生理活性的数据有限。我们评估了颈内动脉给予维拉帕米和尼卡地平对增加新西兰白兔脑血流量的疗效,并比较了这些药物与反向局部内皮素(ET)-1引发的血管痉挛的对抗能力。
在第一组新西兰白兔中,在基线以及增加颈内动脉剂量的维拉帕米和尼卡地平时,记录脑血流量(激光多普勒)和全身血流动力学测量值。在第二组中,在急性植入的颅窗中应用局部ET-1(10^(-4)mol/L)。通过动脉内给予尼卡地平和维拉帕米评估对ET-1诱导的血管痉挛非特异性逆转的剂量反应。
剂量反应研究表明,与维拉帕米相比,颈内动脉给予尼卡地平在增加脑血流量方面更有效。局部ET-1诱导的血管痉挛被尼卡地平完全逆转,被维拉帕米部分逆转。
本研究表明,动脉内给予尼卡地平是一种更强效的脑血管扩张剂,在治疗ET-1诱导的实验性脑血管痉挛方面优于维拉帕米,并支持对这些药物在蛛网膜下腔出血诱导的血管痉挛中的进一步研究。